- Home
- KYMR vs EAT Comparison
KYMR vs EAT Comparison
Compare KYMR & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | EAT |
|---|---|---|
| Founded | 2015 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.1B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | KYMR | EAT |
|---|---|---|
| Price | $137.32 | $196.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 23 |
| Target Price | $145.22 | ★ $264.73 |
| AVG Volume (30 Days) | 916.3K | ★ 1.4M |
| Earning Date | 10-29-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.65 |
| EPS | N/A | ★ 2.64 |
| Revenue | $39,211,000.00 | ★ $5,807,400,000.00 |
| Revenue This Year | $153.48 | $8.63 |
| Revenue Next Year | N/A | $2.94 |
| P/E Ratio | ★ N/A | $74.53 |
| Revenue Growth | N/A | ★ 7.86 |
| 52 Week Low | $61.50 | $111.62 |
| 52 Week High | $142.92 | $254.99 |
Technical Indicators
Market Signals| Indicator | KYMR | EAT |
|---|---|---|
| Relative Strength Index (RSI) | 68.28 | 45.00 |
| Support Level | $104.96 | $186.08 |
| Resistance Level | N/A | $212.23 |
| Average True Range (ATR) | 7.62 | 11.79 |
| MACD | 2.10 | 0.01 |
| Stochastic Oscillator | 83.72 | 29.15 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
About EAT Brinker International Inc.
Brinker International is a leading casual dining operator and franchisor. Chili's, its largest banner and the second-largest casual dining concept in the US, is known for its American/Southwest-inspired menu. In fiscal 2026, the segment generated $5.3 billion in revenue (92% of consolidated sales) across 1,114 company-owned restaurants in the US and 469 franchised locations (the bulk of which are in international markets). The Italian casual-dining concept Maggiano's accounts for the remainder of the business, with 52 domestic units.